NEW YORK ( TheStreet) -- Shares of Cambrex Corporation (NYSE: CBM) were gapping up Friday morning with an open price 10.2% higher than Thursday's closing price. The stock closed at $6.37 Thursday and opened today's trading at $7.02. The average volume for Cambrex has been 201,200 shares per day over the past 30 days. Cambrex has a market cap of $189.2 million and is part of the health care sector and drugs industry. Shares are down 11.3% year to date as of the close of trading on Thursday. Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics. It is primarily involved in the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The company has a P/E ratio of 13.9, below the average drugs industry P/E ratio of 17.3 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Cambrex as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Cambrex Ratings Report. Get more investment ideas from our investment research center.